X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

UPDATED Data Release: Comprehensive Alzheimer Brain Isoform Sequencing (Iso-Seq) Dataset

Tuesday, September 20, 2016

NOTE: This blog was updated with the latest data from the Sequel II System on March 9, 2020.

Alzheimer’s disease (AD) is a devastating neurodegenerative disease that affects ~44 million people worldwide, making it the most common form of dementia. Pathologically it is defined by severe neuronal loss, aggregation of amyloid β (Aβ) in extracellular senile plaques in the brain, and formation of intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau protein. 

Studies looking into disease mechanism have shown that changes in gene expression due to alternative splicing likely contribute to the initiation and progression of AD. Hence, efforts have been made to better understand the gene expression changes in the AD brain by sequencing the transcriptome of affected brain regions.

Figure 1. Transcript length distribution of the Alzheimer Iso-Seq dataset.
FSM = perfect match to a reference transcript. ISM = match to a reference transcript but missing one or more 5’ exons. NIC = novel isoform of known gene using known junctions. NNC = novel isoform of known gene using at least one novel splice site. For more details on transcript classification, see SQANTI2 GitHub.

Recent studies using the PacBio isoform sequencing (Iso-Seq) method demonstrated the advantages of obtaining high-quality, full-length transcript sequences for characterizing complex neural gene splicing [1], fusion cancer genes [2], and potential drug markers [3]. Here we apply the Iso-Seq method from an Alzheimer brain RNA sample. The purpose of releasing the dataset to the public is to provide researchers with a full-length transcriptome reference from which they can develop bioinformatics tools and validate their own findings.

In our final dataset, we obtained 162,290 high-quality, full-length transcript isoforms covering 17,670 genes ranging from 80 bp – 14,288 bp, with an average length of 3.3 kb (Fig. 1). When compared with the reference transcript annotation Gencode v32, almost two-thirds of the transcript isoforms are novel spliced variants (Fig. 2). Rarefaction curve analysis further showed that sampling was saturated at the gene level but novel, rare isoforms continue to be discovered (Fig. 3). The full-length transcripts revealed complex alternative splicing and fusion events (Fig. 4). A public UCSC browser session for the Alzheimer data is available.

Figure 2. Classification of Alzheimer Iso-Seq transcripts against Gencode v32 using SQANTI2 tool. Shaded area indicates proportion of transcripts predicted to have an ORF of >50 aa.

 

Figure 3. Rarefaction curve showing gene-level saturation of the Alzheimer brain sample but not at the isoform level.

 

 

 

 

 

 

 

 

 

 

 

 

 

Library Preparation and Sequencing

An Alzheimer’s Disease Brain total RNA sample was purchased from BioChain. Full-length cDNA library was generated following the Iso-Seq Express protocol. Sequencing was done on the Sequel II System using Sequel II Binding Kit 1.0 and Sequel II Sequencing Kit 1.0 using a single SMRT Cell 8M chip. Sequencing was completed in 2019. 

 

Bioinformatics Analysis

Analysis was done using SMRT Link 8.0 “IsoSeq” protocol to generate full-length, high-quality (HQ) transcript sequences, that were then mapped to the hg38 reference genome using minimap2 (version 2.15-r905). Alignments with less than 99% coverage or 95% identity were removed and redundant transcripts were collapsed using the Cupcake tool. The SQANTI2 tool (v6.0.0) was then used to classify the collapsed, unique transcripts against Gencode v32 and filtered for potential library artifacts such as intra-priming and template switching artifacts [4].

 

Figure 4. UCSC browser screenshot showing complicated alternative splicing and transcriptional readthrough (fusion) events at the PSEN2-COQ8A loci.

 

Use and Citation

We welcome researchers to download and use the dataset for their research. For citation of the dataset, please use:

The Alzheimer brain Iso-Seq dataset was generated by Pacific Biosciences, Menlo Park, California, and additional information about the sequencing and analysis is provided at https://downloads.pacbcloud.com/public/dataset/Alzheimer2019_IsoSeq. The data used in the present study was retrieved from PacBio’s online database at https://downloads.pacbcloud.com/public/dataset/Alzheimer2019_IsoSeq (date of retrieval).

 

References

[1] Flaherty et al., “Neuronal impact of patient-specific aberrant NRXN1α splicing”, Nature Genetics (2019).

[2] Tian et al., “Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia”, Nature Communications (2019).

[3] Vasan et al., “Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors”, Science (2019).

[4] Tardaguila et al., “SQANTI: extensive characterization of long-read transcript sequences for quality control in full-length transcriptome identification and quantification”, Genome Research (2018).

Subscribe for blog updates:

Archives